Bringing the Oncology Community Together

Dr. Brentjens on Treatment With CAR-Modified T Cells

Renier J. Brentjens, MD, PhD
Published Online: Monday, July 1, 2013
Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the treatment of B-cell malignancies with chimeric antigen receptor(CAR)–modified T cells.

This method of treatment goes back almost 10 years, Brentjens says, and started in low-grade B-cell malignancies. As researchers became more comfortable with the technology, they began treating adult B-cell acute lymphoblastic leukemia (ALL), a disease with far worse prognosis. Patients with this disease have a poor prognosis from the time of diagnosis, Brentjens says, and have an even worse prognosis if the disease comes back after initial treatment. The only option for patients who have relapsed is through a salvage chemotherapy regimen, which hopefully gets them back into remission. These patients then undergo an allogeneic bone marrow transplant and hope that the disease does not return. Unfortunately, many patients who relapse never get back into remission, eliminating the option of a transplant.

This is a desperate population that deserves attention, Brentjens says. In a clinical trial, all patients tolerated treatment with CAR–modified T cells and, more significantly, went into a minimal residual disease negative complete remission. Even with highly sensitive detection methods, B cell ALL tumor cells could not be detected. This demonstrated that these patients are optimally primed for subsequent bone marrow transplantation and had the greatest chance of long-term survival.

Related Articles
Adjuvant EGFR Inhibition in Patients With NSCLC
In this segment, panelists discuss the investigation of EGFR inhibitors as adjuvant treatments for patients with resected non-small cell lung cancer.
Treatment of MDS Refractory to Hypomethylating Agent
Panelists discuss the limited number of treatment options that exist for patients with myelodysplastic syndromes who progress on hypomethylating agents, such as azacitidine and decitabine.
New MRD Assay Helps Move Testing Forward in Multiple Myeloma Research
An improved assay for assessing MRD status in patients with multiple myeloma is contributing to the momentum for using MRD as a surrogate endpoint for survival in clinical trials and as a tool with the potential to help guide therapy choices.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

OncLive TV
Oncology Nurses
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.